Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$40.06 - $51.86 $1,041 - $1,348
-26 Closed
0 $0
Q2 2024

Jul 23, 2024

BUY
$36.45 - $47.7 $255 - $333
7 Added 36.84%
26 $1,000
Q3 2023

Oct 25, 2023

BUY
$38.5 - $47.13 $731 - $895
19 New
19 $0
Q2 2023

Aug 10, 2023

BUY
$34.73 - $43.33 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023

BUY
$33.58 - $41.2 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023

BUY
$37.12 - $46.52 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022

BUY
$36.54 - $48.66 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022

SELL
$31.71 - $43.0 $6,785 - $9,202
-214 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$29.88 - $37.04 $328 - $407
11 Added 5.42%
214 $8,000
Q4 2021

Feb 07, 2022

BUY
$25.61 - $35.1 $2,125 - $2,913
83 Added 69.17%
203 $6,000
Q3 2021

Nov 09, 2021

SELL
$33.54 - $40.55 $234 - $283
-7 Reduced 5.51%
120 $4,000
Q2 2021

Aug 13, 2021

BUY
$34.54 - $47.25 $172 - $236
5 Added 4.1%
127 $5,000
Q1 2021

May 13, 2021

BUY
$42.51 - $63.78 $5,186 - $7,781
122 New
122 $5,000
Q4 2020

Feb 02, 2021

BUY
$45.3 - $60.27 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020

BUY
$47.45 - $62.95 $0 - $0
0 New
0 $0
Q2 2020

Aug 13, 2020

BUY
$46.85 - $61.05 $0 - $0
0 New
0 $0
Q1 2020

May 13, 2020

BUY
$41.6 - $63.4 $0 - $0
0 New
0 $0
Q4 2019

Feb 14, 2020

BUY
$53.85 - $65.27 $0 - $0
0 New
0 $0
Q3 2019

Nov 13, 2019

BUY
$59.06 - $72.15 $0 - $0
0 New
0 $0
Q2 2019

Aug 13, 2019

SELL
$62.09 - $86.14 $5,898 - $8,183
-95 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$42.88 - $53.7 $4,073 - $5,101
95 New
95 $5,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $4.83B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.